Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 27;31(6):354.
doi: 10.1007/s00520-023-07800-9.

Financial toxicity experienced by patients with breast cancer-related lymphedema: a systematic review

Jingru Bian  1   2   3 , Aomei Shen  2   3   4 , Wanwan Yang  2   3   5 , Liyuan Zhang  1   2   3 , Wanmin Qiang  6   7
Affiliations

Financial toxicity experienced by patients with breast cancer-related lymphedema: a systematic review

Jingru Bian et al. Support Care Cancer. .

Abstract

Purpose: To perform a systematic review on financial toxicity of breast cancer-related lymphedema.

Methods: Seven databases were searched on September 11, 2022. Eligible studies were identified, analyzed, and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Empirical studies were appraised by the Joanna Briggs Institute (JBI) tools. The Mixed Methods Appraisal Tool version 2018 was used to assess the mixed method studies.

Results: A total of 963 articles were identified, but only 7 articles reporting on 6 studies met the eligibility criteria. A 2-year treatment for lymphedema was approximately USD$14,877 to USD$23,167 in America. In Australia, the average out-of-pocket costs ranged from A$207 to A$1400 (USD$156.26 to USD$1056.83) per year. Outpatient visits, compressed clothing, and hospital admissions were the dominant costs. The financial toxicity was associated with the severity of lymphedema, and patients with heavy financial burden had to reduce other expenses or even forgo the treatment.

Conclusion: Breast cancer-related lymphedema aggravated the economic burden of patients. The included studies showed great variation in the methods used and therefore differences in cost results. The national government should further improve the healthcare system and increase the insurance coverage of lymphedema treatment to alleviate this burden. More research is needed to focus on financial toxicity experience of breast cancer patients with lymphedema.

Implications for cancer survivors: The cost of the ongoing treatment of breast cancer-related lymphedema influences patients' economic situation and quality of life. Survivors need to be informed early about the potential financial burden associated with lymphedema treatment.

Keywords: Breast cancer–related lymphedema; Breast neoplasm; Cost; Financial toxicity; Systematic review.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34. https://doi.org/10.3322/caac.21551 - DOI - PubMed
    1. Hong R, Xu B (2022) Breast cancer: an up-to-date review and future perspectives. Cancer Commun 42(10):913–936. https://doi.org/10.1002/cac2.12358 - DOI
    1. Ezzo J, Manheimer E, McNeely ML et al (2015) Manual lymphatic drainage for lymphedema following breast cancer treatment. Cochrane Database Syst Rev 5:CD003475. Published 2015 May 21. https://doi.org/10.1002/14651858.CD003475.pub2 - DOI
    1. Sayegh HE, Asdourian MS, Swaroop MN et al (2017) Diagnostic methods, risk factors, prevention, and management of breast cancer-related lymphedema: past, present, and future directions. Curr Breast Cancer Rep 9(2):111–121. https://doi.org/10.1007/s12609-017-0237-8 - DOI - PubMed - PMC
    1. DiSipio T, Rye S, Newman B et al (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515. https://doi.org/10.1016/S1470-2045(13)70076-7 - DOI - PubMed

Publication types

LinkOut - more resources